Orgenesis Inc (NADAQ:ORGS) announced a research and development collaboration with Hospital Infantil Universitario Niño Jesús in Madrid, which will establish a point-of-care center utilizing its POCare platform.
The hospital will rely on Orgenesis’ biotech platform to develop and manufacture cell and gene therapies (CGTs). The company’s POCare technology enables hospitals to develop and supply CGTs for patients by combining proprietary knowledge with automated, closed technology to process cell therapies at each point-of-care site.
"Hospital Infantil Universitario Niño Jesús will be an amazing addition to our POCare Network,” Orgenesis CEO Vered Caplan said in a statement. “We believe that our POCare Technologies will enable the hospital to advance this new therapy for the treatment of solid metastatic tumors based on oncolytic virotherapy."
The first collaboration involves the clinical development and validation of T-cell and dendritic cell-based therapies, the company said. Once that project is successfully completed, the parties plan to develop the hospital's oncolytic-based cell therapy technology, Celyvir.
Celyvir represents a new strategy for the treatment of solid metastatic tumors based on oncolytic virotherapy administered by mesenchymal cells obtained from bone marrow.
"We look forward to collaborating with Orgenesis in order to develop our oncolytic based cell therapy,” said Manuel Ramírez, head of the pediatric advanced therapies unit at Hospital Infantil Universitario Niño Jesús.
“By utilizing Orgenesis' CGT Biotech Platform, we seek to reduce the cost of bringing our technology to market, enabling others to use it in their patients, assuring high quality standards by integrating Orgenesis' proprietary POCare Technologies."
Contact Andrew Kessel at [email protected]
Follow him on Twitter @andrew_kessel